{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:11:17Z","timestamp":1761063077934,"version":"build-2065373602"},"reference-count":79,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":370,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:p>Hepatitis C virus affects more than 180 million people worldwide and as many as 4 million people in the United States. Given that most patients are asymptomatic until late in the disease progression, diagnostic screening and evaluation should be performed in patients who display high\u2010risk behaviors associated with acquisition of hepatitis C. Chronic hepatitis C is associated with cirrhosis, hepatic failure, and death; therefore, treatment is aimed at reducing these complications, as well as improving quality of life and minimizing adverse effects. The American Association for the Study of Liver Diseases Practice Guidelines on the Diagnosis, Management, and Treatment of Hepatitis C represent the gold standard for guidance on the management of hepatitis C. Standard treatment for hepatitis C is peginterferon alfa in combination with ribavirin. Currently, two pegylated interferon products are approved by the U.S. Food and Drug Administration for the treatment of hepatitis C. The duration of therapy with peginterferon and ribavirin is dictated by viral genotype and virologic response. Additional therapies are under investigation for treatment of chronic hepatitis C and show early promise of comparative efficacy and fewer adverse effects. Special considerations in certain populations, including patients coinfected with human immunodeficiency virus, those with end\u2010stage renal disease, injection drug users, pregnant women, and pediatric patients, should guide treatment decisions.<\/jats:p>","DOI":"10.1592\/phco.31.1.92","type":"journal-article","created":{"date-parts":[[2010,12,23]],"date-time":"2010-12-23T08:46:26Z","timestamp":1293093986000},"page":"92-111","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Current Therapies for Chronic Hepatitis C"],"prefix":"10.1002","volume":"31","author":[{"given":"McKenzie C.","family":"Ferguson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"1","article-title":"Surveillance for acute viral hepatitis\u2014United States, 2007","volume":"58","author":"Daniels D.","year":"2009","journal-title":"MMWR Surveill Summ"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1331\/JAPhA.2007.06136"},{"key":"e_1_2_1_4_2","unstructured":"National Institutes of Health.Chronic hepatitis C: current disease management November 2006. Available fromhttp:digestive.niddk.nih.govddiseasespubschronichepcindex.htm. AccessedJanuary 8 2010."},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-10-200605160-00004"},{"key":"e_1_2_1_6_2","unstructured":"Centers for Disease Control and Prevention.Disease burden from viral hepatitis A B and C in the United States. Available fromhttp:www.cdc.govhepatitisstatistics.htm. AccessedJanuary 1 2010."},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20941"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22759"},{"key":"e_1_2_1_9_2","unstructured":"Centers for Disease Control and Prevention.Hepatitis C FAQs for health professionals June 2009. Available fromhttp:www.cdc.govhepatitisHCVHCVfaq.htm. AccessedJanuary 3 2010."},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21902"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.069"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/588297"},{"key":"e_1_2_1_13_2","unstructured":"U.S. Food and Drug Administration.FDA news release: FDA approves rapid test for antibodies to hepatitis C virus June 2010. Available fromhttp:www.fda.govNewsEventsNewsroomPressAnnouncementsucm217318.htm. AccessedJune 28 2010."},{"key":"e_1_2_1_14_2","unstructured":"OraSure Technologies Inc.Press release: OraSure Technologies receives FDA approval for OraQuick HCV Rapid Test the first rapid HCV test approved for sale in the U.S. June 2010. Available fromhttp:phx.corporate\u2010ir.netphoenix. zhtmlc99740&pRssLanding&catnews&id1441713. AccessedJuly 7 2010."},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(05)00711-1"},{"key":"e_1_2_1_16_2","first-page":"218","article-title":"Treatment of chronic hepatitis C genotype 4 with peginterferon alpha\u20102a plus ribavirin","volume":"56","author":"Varghese R.","year":"2009","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/0897190008328695"},{"key":"e_1_2_1_18_2","unstructured":"U.S. Food and Drug Administration.Drugs@FDA June 2010. Available fromhttp:www.accessdata.fda.govscriptscderdrugsatfdaindex.cfm. AccessedJuly 13 2010."},{"key":"e_1_2_1_19_2","unstructured":"Sandoz Inc.Ribavirin package insert. Princeton NJ;2008."},{"key":"e_1_2_1_20_2","unstructured":"Hoffman\u2010La Roche Inc.Pegasys (peginterferon alfa\u20102a) package insert. Nutley NJ;2010."},{"key":"e_1_2_1_21_2","unstructured":"Schering Corporation.PegIntron (peginterferon alfa\u20102b) package insert. Kenilworth NJ;2010."},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_1_24_2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2893.2007.00862.x","article-title":"Early virologic response after peginterferon alpha\u20102a plus ribavirin or peginterferon alpha\u20102b plus ribavirin treatment in patients with chronic hepatitis C","volume":"14","author":"Bisceglie AM","year":"2007","journal-title":"J Viral Hepat"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2008.05397.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808010"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.02.015"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21919"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22061"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.04.015"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066403"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22253"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21975"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.01793.x"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22403"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.02.056"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.02.018"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.10.015"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908014"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20467"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042608"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.05.008"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.102558"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2007.00946.x"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01218.x"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.01.039"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-8-200904210-00007"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1086\/595848"},{"key":"e_1_2_1_49_2","unstructured":"Wolters Kluwer Pharma Solutions.Adis R&D insight. Albinterferon alfa\u20102b. Available fromhttp:bi.adisinsight.comframes.aspx. AccessedJanuary 15 2010."},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2009.05.006"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656560802594459"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(06)80739-7"},{"key":"e_1_2_1_53_2","first-page":"433A","article-title":"Treatment week 24 results of weight\u2010based taribavirin versus weight\u2010based ribavirin both with peginterferon alfa\u20102b in na\u00efve chronic hepatitis C, genotype 1 patients [abstract]","volume":"48","author":"Lawitz E.","year":"2008","journal-title":"Hepatology"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2009.05.008"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.03.027"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21774"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.01.041"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806104"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807650"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2007.00476.x"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70264-6"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23020"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.311"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G427"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1086\/588669"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22545"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200825100-00002"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01850309"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e318180803a"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1086\/429501"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2008.01010.x"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.09.008"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1086\/520660"},{"volume-title":"Viral hepatitis in pregnancy. ACOG practice bulletin no. 86","year":"2007","author":"American College of Obstetricians and Gynecologists.","key":"e_1_2_1_74_2"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-005-0065-2"},{"key":"e_1_2_1_76_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.20682"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903304071"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.2165\/0148581-200810060-00003"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20661"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318159836c"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.31.1.92","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.31.1.92","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:52:52Z","timestamp":1761061972000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.31.1.92"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1592\/phco.31.1.92"],"URL":"https:\/\/doi.org\/10.1592\/phco.31.1.92","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}